Navigation Links
Roche Extends Tender Offer for Ventana
Date:1/16/2008

NG OTHER THINGS, STRATEGY, GOALS, PLANS OR INTENTIONS. VARIOUS FACTORS MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY IN THE FUTURE FROM THOSE REFLECTED IN FORWARD-LOOKING STATEMENTS CONTAINED IN THIS DOCUMENT, AMONG OTHERS: (1) PRICING AND PRODUCT INITIATIVES OF COMPETITORS; (2) LEGISLATIVE AND REGULATORY DEVELOPMENTS AND ECONOMIC CONDITIONS; (3) DELAY OR INABILITY IN OBTAINING REGULATORY APPROVALS OR BRINGING PRODUCTS TO MARKET; (4) FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND GENERAL FINANCIAL MARKET CONDITIONS; (5) UNCERTAINTIES IN THE DISCOVERY, DEVELOPMENT OR MARKETING OF NEW PRODUCTS OR NEW USES OF EXISTING PRODUCTS, INCLUDING WITHOUT LIMITATION NEGATIVE RESULTS OF CLINICAL TRIALS OR RESEARCH PROJECTS, UNEXPECTED SIDE-EFFECTS OF PIPELINE OR MARKETED PRODUCTS; (6) INCREASED GOVERNMENT PRICING PRESSURES; (7) INTERRUPTIONS IN PRODUCTION; (8) LOSS OF OR INABILITY TO OBTAIN ADEQUATE PROTECTION FOR INTELLECTUAL PROPERTY RIGHTS; (9) LITIGATION; (10) LOSS OF KEY EXECUTIVES OR OTHER EMPLOYEES; AND (11) ADVERSE PUBLICITY AND NEWS COVERAGE. THE STATEMENT REGARDING EARNINGS PER SHARE GROWTH IS NOT A PROFIT FORECAST AND SHOULD NOT BE INTERPRETED TO MEAN THAT ROCHE'S EARNINGS OR EARNINGS PER SHARE FOR ANY CURRENT OR FUTURE PERIOD WILL NECESSARILY MATCH OR EXCEED THE HISTORICAL PUBLISHED EARNINGS OR EARNINGS PER SHARE OF ROCHE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL VENTANA'S COMMON STOCK. THE TENDER OFFER IS BEING MADE PURSUANT TO A TENDER OFFER STATEMENT ON SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND OTHER RELATED TENDER OFFER MATERIALS) FILED BY ROCHE WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") ON JUNE 27, 2007. THESE MATERIALS, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER, THAT SHOULD BE READ CAREFULLY BE
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
2. Roche Files IND for Second Genmab Antibody
3. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
4. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
5. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
6. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
7. Kosan to Reacquire Epothilone Program From Roche
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
11. Med Ad News Honors Roche as Company of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... and Companies" to their offering. ... based on technologies and applications. The report starts ... for estimation of markets. Technologies include array comparative ...
(Date:9/2/2015)... , Sep. 02, 2015 ... http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition of ... Technologies, Markets and Companies" to their ... includes several technologies besides fluorescence in situ ... multicolor FISH. Molecular cytogenetics includes application of ...
(Date:9/2/2015)... 2, 2015 Australian prostate cancer technology company ... science prize recognising ,outstanding, science that uses its patented ... launch a novel prostate cancer diagnostic test known as ... consortium taking out the peer-reviewed Australian Museum Eureka Science ... This prize is awarded for ground breaking ...
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... , , Bodo Eickhoff and Jrgen van der Bosch , ... D-23845 Borstel, Germany. , Tel.: +49 4537 188458 Fax: +49 4537 ... Abstract , This ... improving PCR efficiency: the TaqMaster. With this enhancer, an integral , ...
... , , , , , , ... RT-PCR has become an essential method that allows researchers to determine , ... the organism, tissue or cell of interest. The basic protocol involves ... present in the sample, followed , by amplification of the gene(s) ...
... , , , Kathryn L. Dudeck and Wendy A. Dustman ... Sciences, , , , , , , ... This application describes the use of the MasterTaq polymerase kit for , ... this polymerase, it was possible to amplify a 675 bp region of the amoA ...
Cached Biology Technology:Enhancing PCR* Efficiency with MasterTaq 2Enhancing PCR* Efficiency with MasterTaq 3Enhancing PCR* Efficiency with MasterTaq 4Enhancing PCR* Efficiency with MasterTaq 5cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 2cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 3cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 4cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 5cMaster RTplusPCR System for increased sensitivity and product length , in RT-PCR 6Amplification of the amoA Gene of Nitrosococcus oceani Bacteria Using , Eppendorf MasterTaq 2Amplification of the amoA Gene of Nitrosococcus oceani Bacteria Using , Eppendorf MasterTaq 3
(Date:9/1/2015)... 1, 2015  Automation and pre-processing are reducing ... screening. This is the first step toward a ... become unintrusive. An assortment of portal scanners, biometric ... investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( http://www.frost.com/nf2b ...
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4
... sclerosis (MS), neuroradiologists and neurologists of the University hospitals ... inflammatory tissue damage, most of which had remained unrecognized ... contrast medium, Gadofluorine M, in magnetic resonance imaging. The ... of the renowned medical journal Brain . ...
... Germany have discovered that methadone, an agent used to ... against leukemia cells, including treatment resistant forms of the ... 1 issue of Cancer Research , a journal ... methadone holds promise as a new therapy for leukemia, ...
... hide their top mate choice, reveals a new study published ... Cell Press journal. They feign disinterest in females ... rival, the tricky males direct their first sexual advances toward ... known to copy other males, mate choices, the researchers noted. ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Lab study shows methadone breaks resistance in untreatable forms of leukemia 2Male fish deceive rivals about their top mate choice 2
... Lumat tube luminometer provides the sensitivity and ... luminometer. Advanced digital photon counting with selected ... of spectral demands. Equipped with up to ... suited for reporter gene assays as well ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
... The Corning CellBIND surface is produced ... makes a more hydrophilic surface giving ... cell growth and yields. CellBIND enhances ... conditions, including reduced serum or serum-free ...
Biology Products: